Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA Read more about Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA
Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies Read more about Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option Read more about Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
Zai Lab Announces Pricing of Public Offering of American Depositary Shares Read more about Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Zai Lab Announces Proposed Public Offering of American Depositary Shares Read more about Zai Lab Announces Proposed Public Offering of American Depositary Shares
Zai Lab Appoints Lonnie Moulder to Board of Directors Read more about Zai Lab Appoints Lonnie Moulder to Board of Directors
ZL-2306 (Niraparib) receives the second funding support from National “Significant New Drugs Development Project” Read more about ZL-2306 (Niraparib) receives the second funding support from National “Significant New Drugs Development Project”
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer Read more about Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project” Read more about ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project”
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer Read more about Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer